<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00305552</url>
  </required_header>
  <id_info>
    <org_study_id>P031008</org_study_id>
    <nct_id>NCT00305552</nct_id>
  </id_info>
  <brief_title>SARCOTHAL. Thalidomide in Skin Sarcoidosis</brief_title>
  <official_title>Randomized Controlled Trial of Thalidomide vs Placebo in Skin Sarcoidosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique - Hôpitaux de Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assistance Publique - Hôpitaux de Paris</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Sarcoidosis is a multisystem disease involving most frequently the lung, the eyes, the lymph
      nodes and the skin. Skin lesions may be disfiguring and impair the quality of life.
      Thalidomide is a multi-target drug that has been shown to be of benefit in skin sarcoidosis
      in case reports. The objective is to assess the efficacy and tolerance of thalidomide in skin
      sarcoidosis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study consists in comparing thalidomide to placebo in skin sarcoidosis. Patients with
      sarcoidosis not necessitating a high-dose corticosteroid regimen, and assessable skin
      lesions, are eligible. They are randomized and receive either thalidomide or placebo for 3
      months. Then they are given Thalidomide for a 3-month open-label period.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2005</start_date>
  <completion_date type="Actual">November 2007</completion_date>
  <primary_completion_date type="Actual">November 2007</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Size of target skin lesions at 3 months.</measure>
    <time_frame>during de study</time_frame>
    <description>Size of target skin lesions at 3 months.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Physician global assessment at 3 months. Functional assessment of other organs. Side-effects at 3 months.</measure>
    <time_frame>during the study</time_frame>
    <description>Physician global assessment at 3 months. Functional assessment of other organs. Side-effects at 3 months.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Sarcoidosis</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>THALIDOMIDE</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>THALIDOMIDE</intervention_name>
    <description>THALIDOMIDE</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Biopsy proven skin sarcoidosis

          -  Assessable target skin lesions

        Exclusion Criteria:

          -  Rapidly evolving sarcoidosis

          -  Patients necessitating a corticosteroid regimen of more than 15mg per day.

          -  Women not willing to undertake a contraceptive method.

          -  Neurologic impairment

          -  Past treatment with Thalidomide

          -  Renal impairment
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michel RYBOJAD, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Assistance Publique - Hôpitaux de Paris</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>HOPITAL Saint Louis, Service de Dermatologie</name>
      <address>
        <city>Paris</city>
        <zip>75010</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>January 2007</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 21, 2006</study_first_submitted>
  <study_first_submitted_qc>March 21, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 22, 2006</study_first_posted>
  <last_update_submitted>April 29, 2011</last_update_submitted>
  <last_update_submitted_qc>April 29, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 2, 2011</last_update_posted>
  <responsible_party>
    <name_title>Myriem CARRIER</name_title>
    <organization>Department Clinical Research of developpement</organization>
  </responsible_party>
  <keyword>Randomized controlled trial</keyword>
  <keyword>Thalidomide vs placebo</keyword>
  <keyword>skin sarcoidosis</keyword>
  <keyword>Thalidomide</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sarcoidosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thalidomide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

